FVC decline in patients with SSc-ILD by use of anti-acid therapy

Conclusion: Post-hoc analyses of data from the SENSCIS trial suggest that the effect of nintedanib on reducing FVC decline in patients with SSc-ILD was similar between patients taking and not taking AAT at baseline. Confounding factors limit interpretation of the differences observed between subgroups based on use of AAT. The effects of GERD and AAT in patients with SSc-ILD warrant further study.

Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Kreuter, M., Nunes, H., Criner, G. J., Sfikakis, P., Stevens, W., Miede, C., Quaresma, M., Alves, M., Raghu, G. Tags: Rare ILD / DPLD Source Type: research